Veracyte, Inc. (VCYT)

Market Cap	2.83B
Revenue (ttm)	479.13M
Net Income (ttm)	26.34M
Shares Out	78.67M
EPS (ttm)	0.34
PE Ratio	107.15
Forward PE	26.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	707,313
Open	36.90
Previous Close	36.73
Day's Range	35.77 - 37.62
52-Week Range	22.61 - 47.32
Beta	2.11
Analysts	Buy
Price Target	40.40 (+12.32%)
Earnings Date	Nov 4, 2025

About VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 30, 2013
• Employees: 824
• Stock Exchange: NASDAQ
• Ticker Symbol: VCYT
• Website: https://www.veracyte.com

Analyst Summary

According to 10 analysts, the average rating for VCYT stock is "Buy." The 12-month stock price target is $40.4, which is an increase of 12.32% from the latest price.

Price Target

$40.4

(12.32% upside)

Analyst Consensus: Buy